Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab-activated D-CIK and Axitinib in Advanced Renal Carcinoma
NCT03736330Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2018
- Primary completion
- Oct 2020
- Modality
- Whole Cell Cancer Vaccines, Lymphokine-Activated Killer Cells, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab + DC-CIK cells in metastatic renal cell carcinoma (mRCC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
pembrolizumab + DC-CIK cells
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03736330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736330.